A study finds more than two-fold differences between counties with the lowest and highest rates of surgery for patients with early stage lung cancer, with socioeconomic and healthcare delivery factors contributing to the gap. The study appears in Chest.
The phase III IMbrave150 study evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) demonstrated statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with sorafenib in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
The phase III ALTA-1L trial evaluating Alunbrig (brigatinib) versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who had not received a prior ALK inhibitor demonstrated reduced risk of disease progression or death.
City of Hope researchers found kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug, Fotivda (tivozanib), compared to an alternative approved by FDA.
Duke Cancer Institute researchers have observed how stem cell mutations quietly arise and spread throughout a widening field of the colon until they eventually predominate and become a malignancy.
The American Cancer Society and Flatiron Health launched a joint grant-making program that supports both organizations' goals of accelerating cancer research and improving treatment and care options for patients.
John P. WilliamsRobert A. IngramEdith P. MitchellThe White House has announced its intent to appoint the following experts to the President's Cancer Panel, which advises the president of the United States on barriers to progress in reducing the burden of cancer:
Chandra P. Belani was named chief science officer of the International Association for the Study of Lung Cancer.
The Association of Community Cancer Centers is collaborating with the AIM at Melanoma Foundation to support the multidisciplinary cancer team in treating patients with squamous cell carcinoma.
Stephen D. Nimer, director of Sylvester Comprehensive Cancer Center, was named the inaugural holder of the Oscar de la Renta Endowed Chair in Cancer Research.
